<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03726177</url>
  </required_header>
  <id_info>
    <org_study_id>aswu 194/7/18</org_study_id>
    <nct_id>NCT03726177</nct_id>
  </id_info>
  <brief_title>Aspirin for Prevention of Preeclampsia</brief_title>
  <official_title>Comparison of Two Doses (81 mg Versus 162mg) of Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylaxis with low-dose aspirin has been recommended to prevent preeclampsia, the rationale
      being that hypertension and abnormalities of coagulation in this disease are caused in part
      by an imbalance between vasodilating and vasoconstricting prostaglandins. Low-dose aspirin
      therapy inhibits thromboxane production more than prostacyclin production and therefore
      should protect against vasoconstriction and pathologic blood coagulation in the placenta.
      Initially, several single-center trials, mostly among women at increased risk for
      preeclampsia, demonstrated a substantial reduction in the risk of proteinuric hypertension as
      well as reductions in the incidences of preterm birth, infants small for gestational age, and
      perinatal death,
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized control trial to estimate the efficacy of two doses (80 mg versus
      160 mg) of aspirin for prevention of preeclampsia in High-Risk Pregnant Women identified in
      the first trimester to be at high risk.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized control trial to estimate the efficacy of two doses (80 mg versus 160 mg) of aspirin for prevention of preeclampsia in High-Risk Pregnant Women identified in the first trimester to be at high risk.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>both participants and researchers will be blinded to the intervention given.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With early Preeclampsia</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of preeclampsia that appear in both groups before 34 weeks of pregnancy.Blood pressure greater than 140/90 on 2 occasions 6 hrs apart and significant proteinuria (greater than 300 mg in 24 hrs) before 34 weeks gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of preeclampsia between 37 and 41</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of preeclampsia that appear in both groups between 37 and 41 weeks of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of cases of Fetal Growth Restriction</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of fetal growth restriction, defined as a fetal weight below the 10th percentile and an abnormal umbilical cord doppler that appear in both groups at any given time during pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of cases of preterm birth</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases delivered before 37 weeks gestation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>aspirin 162 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin 81 mg plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 162 mg</intervention_name>
    <description>Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first</description>
    <arm_group_label>aspirin 162 mg</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 81 mg</intervention_name>
    <description>Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first</description>
    <arm_group_label>aspirin 81 mg plus placebo</arm_group_label>
    <other_name>active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first</description>
    <arm_group_label>aspirin 81 mg plus placebo</arm_group_label>
    <other_name>Placebo to asprin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women presenting prior to 17+0 weeks' gestation.

          -  Moderate to high risk of preeclampsia.

          -  One or more of the following: previous history of preeclampsia, antiphospholipid
             antibodies, pre-existing diabetes, pre-existing hypertension, pre-existing renal
             disease, autoimmune disease, nulliparity, family history of preeclampsia, elevated BMI
             &gt; 25, and maternal age &lt;20 or &gt;35.

          -  Give written informed consent.

        Exclusion Criteria:

          -  Multiple gestations,

          -  fetal aneuploidy

          -  major fetal structural anomaly

          -  bleeding disorder

          -  allergy to aspirin

          -  women already on aspirin or heparin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The population of interest involves women attending the study hospital for antenatal care and delivery</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hany f sallam, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aswan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f sallam, md</last_name>
    <phone>01022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aswan University</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hany f sallam, md</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.ed.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla w Shady, m</last_name>
      <phone>1019240504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>preeclampsia</keyword>
  <keyword>low dose aspirin</keyword>
  <keyword>high risk pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

